scholarly journals Serum and Urine Levels of Sarcosine in Benign Prostatic Hyperplasia and Newly Diagnosed Prostate Cancer Patients

2020 ◽  
Vol 24 (1) ◽  
Author(s):  
Maral Yousefi ◽  
Durdi Qujeq ◽  
Hamid Shafi ◽  
Karimollah Hajian Tilaki
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Cancer Patients ◽  
Prostatic Hyperplasia ◽  
Newly Diagnosed ◽  
Urine Levels ◽  
Serum And Urine

scholarly journals Nanoscale flow cytometry of patient plasma for the detection of prostate cancer-associated extracellular vesicles

2017 ◽  
Vol 3 (2) ◽  
pp. 1-2 ◽  
Author(s):  
Andrew C. Poon ◽  
Johanna Garzon ◽  
Sabine Brett ◽  
Matthew Lowerison ◽  
Karla Williams ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Flow Cytometry ◽  
Benign Prostatic Hyperplasia ◽  
Cancer Patients ◽  
Extracellular Vesicles ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Submicron Particles ◽  
Screening Tests ◽  
Positive Events

Introduction Prostate cancer is the predominant cancer in men, affecting one in seven men during their lifetime. Current tests for prostate cancer include the digital rectal exam and the prostate-specific antigen (PSA) test. Extracellular vesicles (EVs) are submicron particles that participate in intercellular cross-talk by releasing cell mediators such as microRNA, carbohydrates and proteins. While they are known to express the broad tetraspanin family of proteins, i.e. CD9/CD63, prostate cancer-derived EVs have also been found to express PSA and six transmembrane epithelial antigen of the prostate (STEAP1). Traditionally, scientists have purified these EVs through ultracentrifugation. Here we propose a tandem purification of patient plasma, followed by nanoscale flow cytometry (A50+) as a novel method to detect tumour-derived EVs. Materials and Methods Plasma was obtained from healthy volunteers, patients with benign prostatic hyperplasia (BPH), and patients with metastatic prostate cancer. CD9, CD63, PSA and STEAP1 were used as primary antibodies for the purification of EVs from neat plasma. To perform the purification in tandem, Protein G immunoprecipitation using CD9 and PSA was carried out first, followed by immunoaffinity purification with biotinylated CD63 and STEAP1. First and second elutions were collected for the enumeration of dual positive events by A50+. Initial histogram overlays and bivariate plots of neat and purified plasma were computed, then exported as comma-separated values for mathematical modelling by MATLAB. Results Strong dual positive EV populations from patient plasma were optimised, demonstrating that the method enriches tumour-derived EVs from neat samples of patient plasma. This was observed for HVs, patients with benign prostatic hyperplasia, and prostate cancer patients with Gleason 4+4. Enrichment in these purified samples was measured by A50+ and demonstrated by overlaying purified and non-purified histoplots by MATLAB. Additional results show that PSA and STEAP1 can be adapted to detect single or dual positive populations of tumour-associated EVs in prostate cancer patients. Discussions and Conclusions This study suggests that tandem purification of tumour-associated EVs and A50+ analysis from plasma of prostate cancer patients can lead to earlier diagnosis and risk stratification, compared to traditional screening tests and aspiration cytology. Future studies will be directed toward optimizing this detection method for markers of other cancer types to achieve better outcomes in cancer detection and prognosis.

scholarly journals Genome-wide association study of germline copy number variations reveals an association with prostate cancer aggressiveness

Mutagenesis ◽  
2020 ◽  
Vol 35 (3) ◽  
pp. 283-290
Author(s):  
Stefanie Brezina ◽  
Moritz Feigl ◽  
Tanja Gumpenberger ◽  
Ricarda Staudinger ◽  
Andreas Baierl ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Risk Stratification ◽  
Cancer Patients ◽  
Copy Number ◽  
Copy Number Variations ◽  
Prostatic Hyperplasia ◽  
Aggressive Prostate Cancer ◽  
Genome Wide ◽  
Cancer Aggressiveness

Abstract Prostate cancer is a major health burden, being the second most commonly diagnosed malignancy in men worldwide. Overtreatment represents a major problem in prostate cancer therapy, leading to significant long-term quality-of-life effects for patients and a broad socio-ecological burden. Biomarkers that could facilitate risk stratification of prostate cancer aggressiveness at the time of diagnosis may help to guide clinical treatment decisions and reduce overtreatment. Previous research on genetic variations in prostate cancer has shown that germline copy number variations as well as somatic copy number alterations are commonly present in cancer patients, altering a greater portion of the cancer genome than any other type of genetic variation. To investigate the effect of germline copy number variations on cancer aggressiveness we have compared genome-wide screening data from genomic DNA isolated from the blood of 120 patients with aggressive prostate cancer, 231 patients with non-aggressive prostate cancer and 87 controls with benign prostatic hyperplasia from the Prostate Cancer Study of Austria biobank using the Affymetrix SNP 6.0 array. We could show that patients with an aggressive form of prostate cancer had a higher frequency of copy number variations [mean count of copy number segments (CNS) = 12.9, median count of CNS = 9] compared to patients with non-aggressive prostate cancer (mean count of CNS = 10.4, median count of CNS = 8) or control patients diagnosed with benign prostatic hyperplasia (mean count of CNS = 9.3, median count of CNS = 8). In general, we observed that copy number gain is a rarer event, compared to copy number loss within all three patient groups. Furthermore, we could show a significant effect of copy number losses located on chromosomes 8, 9 and 10 on prostate cancer aggressiveness (P = 0.040, P = 0.037 and P = 0.005, respectively). Applying a cross-validation analysis yielded an area under the curve of 0.63. Our study reports promising findings suggesting that copy number losses might play an important role in the establishment of novel biomarkers to predict prostate cancer aggressiveness at the time of diagnosis. Such markers could be used to facilitate risk stratification to reduce overtreatment of prostate cancer patients.

scholarly journals Redox status in benign prostatic hyperplasia and non-metastatic prostate cancer in the Algerian population

2017 ◽  
Vol 1 (2) ◽  
pp. 42-43
Author(s):  
Rima Mouhoub ◽  
Karima Haddad ◽  
Sarah Goumeri ◽  
Abdel-Aziz Chibane ◽  
Raouf Oucherif ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Cancer Patients ◽  
Catalase Activity ◽  
Metastatic Prostate Cancer ◽  
Group Versus ◽  
Antioxidant Defense System ◽  
Redox Status ◽  
Prostatic Hyperplasia ◽  
Control Group

Background: Depletion of cellular antioxidants can result from free radical formation due to normal endogenous reactions and the ingestion of exogenous substances and environmental factors. The levels of reactive oxygen species (ROS) have been shown to be significantly altered in malignant cells and in primary cancer tissues. We undertook the present study to investigate the possible alteration of oxidant/antioxidant status in Algerian patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Methods: In total, 89 subjects made up of 26 patients with non-metastatic prostate cancer, 31 with benign prostatic hyperplasia (BPH), and 32 controls participated in this study. The concentrations of plasmatic malondialdehyde (MDA), erythrocytes catalase activity (CAT), and the plasma glutathione levels (GSH) were estimated using standard procedures. Results: The results showed that MDA concentrations were significantly increased while erythrocyte catalase activity was significantly decreased in the prostate cancer group versus controls (P < 0.01) and BPH group (P < 0.05). GSH levels were lowered in prostate cancer patients versus control group with no significant changes. Conclusions: Our results suggest that an alteration in the lipid peroxidation index with concomitant changes in the antioxidant defense system in prostate cancer patients compared with controls. We hypothesize that an altered pro-oxidant–antioxidant balance may lead to an increase in oxidative damage and consequently may play an important role in prostate carcinogenesis.

Evaluation of the plasma level of long non‐coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients

2020 ◽  
Vol 22 (10) ◽  
Author(s):  
Setareh Rezatabar ◽  
Emadoddin Moudi ◽  
Farzin Sadeghi ◽  
Soraya Khafri ◽  
Tayebeh Azramezani Kopi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Plasma Level ◽  
Cancer Patients ◽  
Prostatic Hyperplasia ◽  
Newly Diagnosed ◽  
Non Coding Rna ◽  
Long Non Coding Rna

598: Increased Risk of Newly Diagnosed Comorbidities in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

2007 ◽  
Vol 177 (4S) ◽  
pp. 200-200 ◽  
Author(s):  
Andrea Gallina ◽  
Pierre I. Karakiewicz ◽  
Jochen Walz ◽  
Claudio Jeldres ◽  
Quoc-Dien Trinh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Increased Risk

289: Assessment of Indirect Costs of Newly Diagnosed Prostate Cancer Patients

2007 ◽  
Vol 177 (4S) ◽  
pp. 97-97
Author(s):  
Ravishankar Jayavedappa ◽  
Sumedha Chhatre ◽  
Richard Whittington ◽  
Alan J. Wein ◽  
S. Bruce Malkowicz
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Indirect Costs ◽  
Newly Diagnosed
Sign in / Sign up

Export Citation Format

Share Document